TaiMed Biologics

4147.TWO

2.72 USD

-0.07

-2.51%

Overview

Last close

2.72 usd

Market cap

743.12M usd

52 week high

3.60 usd

52 week low

2.03 usd

Target price

5.41 usd

Valuation

P/E

N/A

Forward P/E

1111.1111

Price/Sales

36.4187

Price/Book Value

5.6923

Enterprise Value

726.98M usd

EV/Revenue

35.6277

EV/EBITDA

543.5886

Key financials

Revenue TTM

20.40M usd

Gross Profit TTM

7.87M usd

EBITDA TTM

-3.39M usd

Earnings per Share

-0.03 usd

Dividend

N/A usd

Total assets

148.40M usd

Net debt

N/A usd

About

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment. In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.